Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018. We intend to continue to expand our pipeline with the goal of creating a leading urology company by developing, commercializing and acquiring innovative therapies.
Urovant’s second investigational product candidate, hMaxi-K, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Copyright West LLC. Minimum 15 minutes delayed.